Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (19924)	3/21/1999 12:53:00 PM
From: blankmind	Read Replies (2) \| Respond to of 23519

My advice to anyone holding VVUS is to just hold it. - all these good news could or could not materialize. And as we've seen with FDA Plant approval, country approvals, etc... the stock price may not move correctly.

To: Frostman who wrote (19924)	3/21/1999 2:28:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 23519

Frostman <<You bet, I would be happy with a figure that adds twenty-five cents per share earnings to VIVUSQ3. :-)>> Frosty: Although milestone payments and partnership agreements are positive actions, Rx specification, sales and earnings are the true drivers of future stock prices and higher EPS. The major problems with the Japanese Pharma market (the 2nd largest in the world) are the clinical study requirements and regulatory approval time. Japan usually requires clinical studies with Japanese patients. Accordingly, it takes a long time and expense to conduct the necessary studies. After the filing, the Japanese Ministry of Health and Welfare takes over with "most drugs needing a year and a half to get approval." As noted by the 1/25/99 issue of the Asian Wall Street Journal, the Viagra approval was "unusually quick". www3.techstocks.com BigKNY3